Business Summary: Agenus Inc. is an immuno-oncology (I-O) company targeting cancer with a comprehensive pipeline of immunological agents. The company is focused on expanding patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants. Its I-O portfolio is driven by several platforms and programs, which include multiple antibody discovery platforms, antibody candidate programs, its saponin-based vaccine adjuvant platform, and a pipeline of novel allogeneic invariant natural killer T cell (iNKT) therapies for treating cancer and other immune-mediated diseases, controlled by MiNK. Its antibody candidate programs include botensilimab (BOT) and balstilimab (BAL) (a PD-1 blocking antibody). The Company has secured committed manufacturing capacity to support BOT+BAL supply needs for its clinical trials, global access programs and future commercialization.
Financial Summary: BRIEF: For the three months ended 31 March 2026, Agenus Inc revenues increased 40% to $33.7M. Net income applicable to common stockholders totaled $39.2M vs. loss of $25.3M. Revenues reflect United States segment increase of 43% to $33.7M. Net Income reflects R & D expenses decrease of 44% to $11.6M (expense), GENERAL AND ADMINISTRATIVE decrease of 53% to $6.2M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$1.03 to $1.03.